ScaleReady is presenting a poster in collaboration with our partner’s Bio-Techne promoting TcBuster. Please stop by our poster at position #44 to learn more on the below:

“We have developed a non-viral transposase-based editing platform to overcome current viral limitations, which allows for rapid cell manufacture, and reduced cell manufacturing cost. Using directed evolution, we engineered a hyperactive mutant (TcBuster-M™) that has improved integration rates using less plasmid DNA transposon.

Finally, we have conducted direct comparisons against lentiviral-engineered CAR-Ts, demonstrating TcB-M engineered CAR-Ts had higher integration percentage, comparable copy number per genome, and safer genome insertion loci.”